14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:TSRO
Delisted

TESARO Fund Price (Quote)

$74.96
+0 (+0%)
At Close: Feb 13, 2019

Range Low Price High Price Comment
30 days $0.0060 $169.56 Wednesday, 13th Feb 2019 TSRO stock ended at $74.96. During the day the stock fluctuated 0% from a day low at $74.96 to a day high of $74.96.
90 days $113.65 $133.77
52 weeks $171.20 $133.77

Historical TESARO prices

Date Open High Low Close Volume
Aug 14, 2018 $27.20 $28.22 $27.17 $28.04 1 467 542
Aug 13, 2018 $26.65 $27.19 $26.32 $27.16 1 076 402
Aug 10, 2018 $27.06 $27.59 $26.57 $26.67 940 918
Aug 09, 2018 $26.90 $28.18 $26.69 $27.19 1 255 431
Aug 08, 2018 $27.76 $27.95 $26.08 $26.86 2 144 162
Aug 07, 2018 $27.17 $27.96 $25.96 $27.66 2 389 384
Aug 06, 2018 $26.77 $28.37 $25.62 $27.02 4 637 223
Aug 03, 2018 $31.06 $32.48 $26.75 $26.97 14 486 484
Aug 02, 2018 $34.37 $35.89 $33.25 $35.28 3 269 687
Aug 01, 2018 $34.65 $35.30 $34.04 $34.73 2 007 222
Jul 31, 2018 $34.61 $35.12 $34.15 $34.83 1 376 575
Jul 30, 2018 $34.95 $35.75 $34.27 $34.44 1 297 649
Jul 27, 2018 $36.24 $36.46 $34.74 $35.12 1 141 433
Jul 26, 2018 $35.52 $36.60 $34.54 $36.24 2 328 094
Jul 25, 2018 $38.14 $38.86 $35.39 $35.60 3 267 510
Jul 24, 2018 $40.44 $40.83 $38.02 $38.14 1 734 322
Jul 23, 2018 $39.13 $40.76 $38.60 $40.06 1 455 808
Jul 20, 2018 $40.15 $40.49 $39.10 $39.24 1 389 821
Jul 19, 2018 $40.93 $41.05 $40.05 $40.23 1 136 991
Jul 18, 2018 $40.65 $41.08 $39.43 $40.96 1 631 438
Jul 17, 2018 $40.46 $41.23 $40.00 $40.34 1 487 487
Jul 16, 2018 $44.85 $44.85 $40.40 $40.55 2 616 828
Jul 13, 2018 $44.88 $45.89 $44.41 $44.90 949 529
Jul 12, 2018 $45.90 $45.90 $43.80 $44.84 960 148
Jul 11, 2018 $44.62 $46.27 $44.07 $45.60 1 154 462
Click to get the best stock tips daily for free!

About TESARO

TESARO, Inc., an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States and internationally. Its product portfolio consist of Rolapitant, a neurokinin-1 receptor antagonist, which is in phase 1 intravenous clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an orally active and potent poly p... TSRO Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT